Cotinga Pharmaceuticals Inc. (COT.V) (COT) Stock Price, News & Analysis

Company Overview

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Key Stats

• Today's Range: C$0.04 to C$0.04
• 50-Day Range: C$0.04 to C$0.04
• 52-Week Range: C$0.02 to C$0.12
• Volume: 1,000 shs
• Average Volume: 20,281 shs
• Market Capitalization: C$769.51 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:COT
• CIK: N/A
• Web: cotingapharma.com
• Phone: +1-519-8585157
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.05
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 17.50
• Book Value: C($0.18) per share
• Price / Book: -0.20

Miscellaneous

• Outstanding Shares: 21,986,000
• Free Float: N/A
• Market Cap: C$769.51 thousand
• Optionable: Not Optionable
• Beta: N/A